Vue.component('supd-overview', { template: '
The percentage of individuals ages 40 to 75 years who were dispensed a medication for diabetes that receive a statin medication.
' + 'A higher rate indicates better performance.
' + 'Intended Use
' + 'Performance measurement for health plans.
' + 'Data Sources
' + 'Prescription claims data.
' + 'Denominator
' + 'Individuals ages 40 to 75 years with ≥2 prescription claims on different dates of service for any diabetes medication during the measurement year.
' + 'Exclusions
' + 'Numerator
' + 'Individuals from the denominator with ≥1 prescription claims for a statin medication during the measurement year.
' + 'Diabetes care in the United States has improved over recent years, evident by increased proportion of patients meeting A1C, blood pressure, and LDL goals.' +
'
The American Diabetes Association and American College of Cardiology/American Heart Association guidelines congruently recommend moderate- to high-intensity statins to be used as a first line lipid-lowering agent for patients with diabetes age 40-75 for prevention of cardiovascular disease.' +
'
This Pharmacy Quality Alliance (PQA) endorsed measure was created to determine the proportion of patients who were dispensed two diabetes medications within a year that also receive a statin medication. This measure uses pharmacy claims as a proxy for diabetes diagnosis. The reliability of this proxy method was reconfirmed by two independent organizations in partnership with PQA. Results of this investigation found that using a minimum of 2 diabetic prescriptions is a valid predictor of a diabetes diagnosis; both organizations found an above 90% positive predictive value.
' + 'Individuals in hospice care are excluded because the use of statins is meant for long-term therapeutic benefit, as these medications decrease the risk of cardiovascular events, and these therapeutic regimens may not be present or useful at the end of life or for palliative care.' +
'
With this measure, a higher proportion indicates a better result. In using claims data, it is not possible to capture patient specific reasons to not receive a statin, for example, allergy or adverse reaction, so the performance rate goal is not expected to be 100%. Furthermore, these situations are not likely to disproportionately impact performance across plans.
' + 'This is a health plan performance measure that retrospectively evaluates the percentage of individuals ages 40 to 75 years who were dispensed medications for diabetes that receive a statin medication during the measurement year using administrative data. This measure is not designed to be used for clinical decision making. It is intended for retrospective, population level assessment and is not intended to guide individual patient-care decisions.
' + 'Last Update: 7 Oct 2019
' + 'Statins are taken for the long-term therapeutic benefits, which include decreased risk of cardiovascular events. These therapeutic regimens may not be present or useful at the end of life or for palliative care.
Individuals with ESRD are excluded because evidence from major clinical trials has failed to demonstrate benefits for statin therapy in patients with ESRD.